<prompt> Raynauds phenomenon seen in all EXCEPT:SclerodermaDermatomyositisJuvenile rheumatoid ahritisSLE  <response>: Juvenile rheumatoid ahritisREF: Schwazs Principles of Surgery 9 edition Chapter 23. Aerial Disease, Harrisons Internal Medicine 17th edition Chapter 243 Table 243-1 Raynauds phenomenon is seen in Rheumatoid ahritis not Juvenile Rheumatoid ahritis The term Raynauds phenomenon applies to a heterogeneous symptom array associated with peripheral vasospasm, more commonly occurring in the upper extremities The majority of patients are young women 40 years of age and is often bilateral. There is no cure for Raynaudssyndrome, thus all treatments mainly palliate symptoms and decrease the severity and, perhaps, frequency of attacks. The majority 90 of patients will respond to avoidance of cold and other stimuli. The remaining 10 of patients with more persistent or severe syndromes can be treated with a variety of vasodilatory drugs. Calcium-channel blockers such as diltiazem and nifedipine are the drugs of choice. Raynauds phenomenon is broadly separated into two categories: the idiopathic variety, termed Raynauds disease, and the secondary variety, which is associated with other disease states or known causes of vasospasm CLASSIFICATION OF RAYNAUDS PHENOMENON Primary or idiopathic Raynauds phenomenon: Raynauds disease Secondary Raynauds phenomenon Collagen vascular diseases: scleroderma, systemic lupus erythematosus, rheumatoid ahritis, dermatomyositis, polymyositis Aerial occlusive diseases: atherosclerosis of the extremities, thromboangiitis obliterans, acute aerial occlusion, thoracic outlet syndrome Pulmonary hypeension Neurologic disorders: interveebral disk disease, syringomyelia, spinal cord tumors, stroke, poliomyelitis, carpal tunnel syndrome Blood dyscrasias: cold agglutinins, cryoglobulinemia, cryofibrinogenemia, myeloproliferative disorders, WaldenstrOms macroglobulinemia Trauma: vibration injury, hammer hand syndrome, electric shock, cold injury, typing, piano playing Drugs: ergot derivatives, methysergide, Beta-adrenergic receptor blockers, bleomycin, vinblastine, cisplatin 